Kooshyar Mohammad Mahdi, Ayatollahi Hossein, Keramati Mohammad Reza, Sadeghian Mohammad Hadi, Miri Mohsen, Sheikhi Maryam
Hematology Department, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6653-6. doi: 10.7314/apjcp.2013.14.11.6653.
The single most common proto-oncogene change in human neoplasms is a point mutation in RAS genes. A wide range of variation in frequency of KRAS mutations has been seen in hematologic malignancies. Despite this, RAS roles in leukemogenesis remain unclear. The frequency of KRAS mutations in CML has been reported to be between zero an 10%. Many attempts have been done to develop an anti-RAS drug as a therapeutic target. .
This cross sectional study was performed in Mashhad University of Medical Sciences, Mashhad, Iran from 2010-2012. In 78 CML patients (diagnosed according to WHO 2008 criteria) in chronic or accelerated phases, KRAS mutations in codons 12 and 13 were analyzed using a modified PCR- restriction fragment length polymorphism (RFLP) method.
We did not detect any KRAS mutations in this study.
KRAS mutations are overall rare in early phase CML and might be secondary events happening late in leukemogenesis cooperating with initial genetic lesions.
人类肿瘤中最常见的原癌基因改变是RAS基因的点突变。在血液系统恶性肿瘤中，KRAS突变频率存在广泛差异。尽管如此，RAS在白血病发生中的作用仍不清楚。据报道，慢性粒细胞白血病（CML）中KRAS突变频率在0%至10%之间。人们已经进行了许多尝试来开发一种抗RAS药物作为治疗靶点。
本横断面研究于2010年至2012年在伊朗马什哈德医科大学进行。对78例处于慢性期或加速期的CML患者（根据WHO 2008标准诊断），采用改良的聚合酶链反应-限制性片段长度多态性（RFLP）方法分析第12和13密码子的KRAS突变。
本研究未检测到任何KRAS突变。
KRAS突变在CML早期总体罕见，可能是白血病发生后期与初始基因病变协同作用的继发事件。
